# A Study of HDM2020 in Patients With Advanced Solid Tumors

> **NCT07098052** · PHASE1 · RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** HDM2020

## Key facts

- **NCT ID:** NCT07098052
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-11
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-05-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07098052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07098052, "A Study of HDM2020 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07098052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*